Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>Key Points</jats:title> <jats:p>Targeted NGS of relapsed/refractory CLL reveals a high incidence of concurrent mutations that mostly affect the TP53, ATM, and SF3B1 genes. Concurrent mutations of the TP53, ATM, and/or SF3B1 genes confer short survival in patients with relapsed/refractory CLL.</jats:p>

Original publication

DOI

10.1182/blood-2015-05-647578

Type

Journal article

Journal

Blood

Publisher

American Society of Hematology

Publication Date

29/10/2015

Volume

126

Pages

2110 - 2117